Sportsbet.io - ブックメーカーとスポーツベッティングの本格 ...

Japanese English Japanese English Access Contact Site Map Message from the Director Mission Organization Organization Chart Research Divisions Administrative Divisions Facilities and Equipment Logo Access Links iPS Cell Research Fund Request for Support Financial Report Contact Principal Investigators Publications Research Overview Protocols on iPS Cells Training Programs Material Distribution Non-Profit Organization Profit Organization CiRA IP iPS Cell Stock for Regenerative Medicine Internship Program Life at CiRA Graduate Program For High School Students FAQ What are iPS cells? For patients For researchers Other Questions iPS MASTER The road to iPS cells (Poster) Photo Galleries Videos News Media Gallery CiRA Reporter Learn More Open Position Closed T-CiRA Joint Program Fellowships Altos-CiRA Research Project News & Events News & Events Home　›　News & Events　›　2024　›　Research　›　Inhibition of oxidative phosphorylation points to a new potential treatment for FOP News March 11, 2024 Inhibition of oxidative phosphorylation points to a new potential treatment for FOP A research team, led by CiRA Professor Junya Toguchida in collaboration with Assistant Professor Yonghui Jin and graduated student Liping Sun at the Institute for Life and Medical Sciences, Kyoto University, has identified a promising therapeutic target for an intractable genetic disease, Fibrodysplasia Ossificans Progressiva (FOP). Using FOP patient-derived iPS cells, they uncovered that the activation of oxidative phosphorylation (OXPHOS) plays a pivotal role in the development of heterotopic ossification in FOP. Furthermore, their findings demonstrate that an OXPHOS inhibitor effectively suppresses this activation in progenitor cells, thus significantly inhibiting heterotopic ossification. FOP is a rare genetic disease characterized by progressive and systemic heterotopic ossification (abnormal bone formation in soft tissues). Most FOP patients harbor mutations in the ACVR1 gene, encoding one of the type I BMP (Bone Morphogenic Protein) receptors. Through a previous collaboration with CiRA Associate Professor Makoto Ikeya, Toguchida's team utilized iPS cells derived from FOP patients to identify a key molecule implicated in triggering heterotopic ossification. In that study, they found Activin A to erroneously transmit BMP signaling through mutant ACVR1, resulting in mTORC1 complex activation. This aberrant mTORC1 activation, in turn, promotes the chondrogenic differentiation of mesenchymal stem cells (MSCs) induced from FOP-iPSCs but not from mutation-rescued FOP-iPSCs. Based on these results, they initiated the clinical trials using a mTORC1 inhibitor, rapamycin. However, the molecular events downstream of activated mTORC1 remained unclear. In the current study, the researchers first compared gene expression profiles of FOP-MSCs and mutation-rescued FOP-MSCs during chondrogenesis and revealed an enrichment of OXPHOS-associated genes in FOP-MSCs. Consistent with this, they uncovered the upregulation of TCA cycle metabolites and increased ATP production during chondrogenesis, respectively, through mass spectrometry and oxygen consumption rate measurements. Remarkably, treatment with IACS-010759 (IACS), an inhibitor of the mitochondrial respiratory complex I, significantly suppressed the chondrogenic differentiation of FOP-MSCs. These findings highlight the pivotal role of OXPHOS in Activin A-driven chondrogenesis of FOP-MSCs. To examine the pathogenic contribution of OXPHOS in vivo, the researchers induced heterotopic ossification by pinch injury in FOP model mice carrying the mutated human ACVR1 gene. Consistent with in vitro findings, chondrogenic differentiation in injured tissues was inhibited by IACS treatment, resulting in the suppression of heterotopic ossification. Fibro-adipogenic progenitors (FAPs), identified as PDGFRα-positive cells in skeletal muscles possessing fibrogenic and adipogenic properties, are considered the pathogenic cells responsible for heterotopic ossification in FOP. Notably, the research team observed injury to trigger the upregulation of FAP-associated genes, which was attenuated by IACS treatment. Moreover, histological analysis revealed the injury-induced proliferation of PDGFRα-positive cells, which were also positive for TOMM20, a marker for mitochondrial biogenesis. Remarkably, treatment with IACS led to the disappearance of these PDGFRα and TOMM20 double-positive cells in injured tissues. These findings indicate that IACS impedes chondrogenesis and heterotopic ossification by inhibiting OXPHOS activation in FAPs, thus advancing our understanding of the molecular mechanisms underlying heterotopic ossification in FOP as well as providing a novel therapeutic avenue for treatment. Inhibition of injury-induced chondrogenesis and heterotopic ossification by IACS. A, Gene set for chondrogenic differentiation. B, Chondrogenic differentiation 7 days after pinch injury. C, Heterotopic ossification scanned by µCT 21 days after pinch injury. D, Quantification of heterotopic ossification. Paper Details Journal: Life Science Alliance Title: Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva Authors: Liping Sun1, Yonghui Jin1*, Megumi Nishio2, Makoto Watanabe3, Takeshi Kamakura1, Sanae Nagata2, Masayuki Fukuda1, Hirotsugu Maekawa2, Shunsuke Kawai2, Takuya Yamamoto2,4,5, Junya Toguchida1,2* *: Corresponding authors Author Affiliations: Institute for Life and Medical Sciences, Kyoto University Center for iPS Cell Research and Application, Kyoto University Life Science Research Center, Shimadzu Corporation Institute for the Advanced Study of Human Biology, Kyoto University Center for Advanced Intelligence Project, RIKEN doi: 10.26508/lsa.202302219 News CiRA Reporter Learn More Media Gallery About CiRA Message from the Director Mission Organization Facilities and Equipment Logo Access iPS Cell Research Fund Links Contact Research Activities Principal Investigators Publications Research Overview Protocols on iPS Cells Training Programs Material Distribution CiRA IP iPS Stock Cells for Regenerative Medicine Education & Career Internship Program Graduate Program For High school Students Life at CiRA For the Public FAQ iPS MASTER The road to iPS cells Videos News & Events News CiRA Reporter Learn More Media Gallery Jobs Open Positions Closed T-CiRA Altos-CiRA Fellowships Access　|　Contact　|　Site Map Site Policy - Privacy Policy Copyright © Center for iPS Cell Research and Application, Kyoto University. All rights reserved. About CiRA Research Activities Education & Career For the Public News & Events Jobs Access iPS Cell Research Fund Contact